218 related articles for article (PubMed ID: 29914162)
1. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
Müller C; Guzik P; Siwowska K; Cohrs S; Schmid RM; Schibli R
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914162
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer.
Müller C; Schibli R; Krenning EP; de Jong M
J Nucl Med; 2008 Apr; 49(4):623-9. PubMed ID: 18344429
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy.
Reber J; Haller S; Leamon CP; Müller C
Mol Cancer Ther; 2013 Nov; 12(11):2436-45. PubMed ID: 24030631
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting using 67Ga-DOTA-Bz-folate--investigations of methods to improve the tissue distribution of radiofolates.
Müller C; Vlahov IR; Santhapuram HK; Leamon CP; Schibli R
Nucl Med Biol; 2011 Jul; 38(5):715-23. PubMed ID: 21718947
[TBL] [Abstract][Full Text] [Related]
6. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo.
Müller C; Brühlmeier M; Schubiger PA; Schibli R
J Nucl Med; 2006 Dec; 47(12):2057-64. PubMed ID: 17138750
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy.
Müller C; Mindt TL; de Jong M; Schibli R
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):938-46. PubMed ID: 19183997
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys.
Müller C; Schibli R; Forrer F; Krenning EP; de Jong M
Nucl Med Biol; 2007 Aug; 34(6):603-8. PubMed ID: 17707799
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of an innocuous drug cocktail to improve the quality of folic acid targeted nuclear imaging in preclinical research.
Müller C; Reber J; Schlup C; Leamon CP; Schibli R
Mol Pharm; 2013 Mar; 10(3):967-74. PubMed ID: 23394590
[TBL] [Abstract][Full Text] [Related]
10. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
[TBL] [Abstract][Full Text] [Related]
11. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast.
Reber J; Struthers H; Betzel T; Hohn A; Schibli R; Müller C
Mol Pharm; 2012 May; 9(5):1213-21. PubMed ID: 22509996
[TBL] [Abstract][Full Text] [Related]
12. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
13. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice.
Müller C; Reddy JA; Leamon CP; Schibli R
Mol Pharm; 2010 Apr; 7(2):597-604. PubMed ID: 20199053
[TBL] [Abstract][Full Text] [Related]
14. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
[TBL] [Abstract][Full Text] [Related]
15.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
16. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
17. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
18. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
19. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate.
Müller C; Forrer F; Schibli R; Krenning EP; de Jong M
J Nucl Med; 2008 Feb; 49(2):310-7. PubMed ID: 18199624
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Properties of
Larenkov A; Rakhimov M; Lunyova K; Klementyeva O; Maruk A; Machulkin A
Molecules; 2020 Jun; 25(11):. PubMed ID: 32545327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
